Ith antihyperglycaemic agents: an update. Drug Saf 2005, 28:60131. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: Metformin, sulfonylureas, or other antidiabetes medication and also the chance of lactic acidosis or hypoglycemia: a nested case ontrol examination. Diabetes Care 2008, 31:2086091. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P: The partnership in between metformin treatment plus the fasting plasma lactate in variety 2 diabetes: the fremantle diabetes research. Br J Clin Pharmacol 2001, 52:13744. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in style 2 diabetes mellitus: systematic assessment and meta-analysis. Arch Intern Med 2003, 163:2594602. Kanai Y, Lee WS, You G, Brown D, Hediger MA: The human kidney minimal affinity Na+/glucose cotransporter SGLT2. Delineation of your main renal reabsorptive mechanism for D-glucose.PT2399 J Clin Invest 1994, 93:39704.Remdesivir Wright EM, Hirayama BA, Loo DF: Lively sugar transport in well being and sickness. J Intern Med 2007, 261:323. Handlon AL: Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005, 13:1531540. Hussey E, Clark R, Amin D, Kipnes M, O’Connor-Semmes R, O’Driscoll E, Leong J, Murray S, Dobbins R, Layko D, et al: The single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in nutritious volunteers and topics with kind 2 diabetes mellitus. J Clin Pharmacol 2010, 50:62335. Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O’Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJR: Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in nutritious overweight and obese topics: a randomized double-blind study.PMID:30125989 J Clin Pharmacol 2010, 50:63646. Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, eleven:798. Isaji M: Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Medication 2007, 8:28592. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, enhanced glycemic management above two weeks in individuals with kind 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:51319. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M: Dapagliflozin, a novel SGLT2 inhibitor, induces dosedependent glucosuria in healthier subjects. Clin Pharmacol Ther 2009, 85:52026. Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y: Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic medicines. Curr Med Chem 2004, 11:2717724. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev 2005, 21:318. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the significant purpose of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007, 320:32330.26. Jabbour SA, Goldstein BJ: Sodium glucose co-transporter two inhibitors: blocking renal tubular reabsorption of glucose to enhance glycaemic manage in patients with diabetes. Int J Clin Pract 2008, 62:1279284. 27. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M: Remogliflozin etabonate, i.